Suppr超能文献

浸润性小叶癌和导管癌的发病率趋势。

Trends in incidence rates of invasive lobular and ductal breast carcinoma.

作者信息

Li Christopher I, Anderson Benjamin O, Daling Janet R, Moe Roger E

机构信息

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MP 381, PO Box 19024, Seattle, Wash 98109-1024, USA.

出版信息

JAMA. 2003 Mar 19;289(11):1421-4. doi: 10.1001/jama.289.11.1421.

Abstract

CONTEXT

Research has suggested that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast cancer risk and that CHRT use is more strongly associated with the risk of invasive lobular breast carcinoma than that of invasive ductal carcinoma. Lobular carcinoma is less common than ductal carcinoma but can be more difficult to diagnose because of its subtle elusive infiltrative pattern.

OBJECTIVE

To evaluate trends in invasive lobular and ductal carcinoma incidence rates from 1987 through 1999, during which time use of CHRT increased in the United States.

DESIGN

Descriptive epidemiologic study.

SETTING

Nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and that cover Atlanta, Ga; Detroit, Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut, Hawaii, Iowa, New Mexico, and Utah.

POPULATION

Women 30 years of age and older residing in the areas covered by the 9 SEER registries.

MAIN OUTCOME MEASURES

Proportional changes in incidence rates of invasive lobular and ductal carcinoma among women with no prior history of breast cancer.

RESULTS

A total of 190 458 women were included in this analysis who were identified through the registries as having invasive breast cancer; 7682 of the 198 140 potentially eligible women (ie, those identified as not having in situ breast cancer) were excluded from this analysis because stage of cancer was unknown. Invasive breast cancer incidence rates adjusted for age and for SEER historic stage increased 1.04-fold (95% confidence interval [CI], 1.004-1.07) from 1987-1999 (206.7/100 000 to 214.1/100 000, age-adjusted). However, incidence rates of tumors classified as lobular increased 1.52-fold (95% CI, 1.42-1.63), and those classified as mixed ductal-lobular increased 1.96-fold (95% CI, 1.80-2.14); rates of these types combined increased 1.65-fold (95% CI, 1.55-1.78) (19.8/100 000 to 33.4/100 000, age-adjusted). In contrast, ductal carcinoma rates remained largely constant (153.8/100 000 to 155.3/100 000, age-adjusted; proportional change, 1.03 [95% CI, 0.99-1.06]). The proportion of breast cancers with a lobular component increased from 9.5% in 1987 to 15.6% in 1999.

CONCLUSIONS

Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography.

摘要

背景

研究表明,联合使用雌激素和孕激素的激素替代疗法(CHRT)会增加患乳腺癌的风险,且CHRT的使用与浸润性小叶乳腺癌风险的关联比浸润性导管癌更强。小叶癌比导管癌少见,但因其细微、难以捉摸的浸润模式,可能更难诊断。

目的

评估1987年至1999年期间浸润性小叶癌和导管癌发病率的变化趋势,在此期间美国CHRT的使用有所增加。

设计

描述性流行病学研究。

地点

参与美国国立癌症研究所监测、流行病学和最终结果(SEER)项目的9个癌症登记处,覆盖佐治亚州亚特兰大;密歇根州底特律;加利福尼亚州旧金山-奥克兰;华盛顿州西雅图;以及康涅狄格州、夏威夷州、爱荷华州、新墨西哥州和犹他州。

研究对象

居住在9个SEER登记处覆盖地区的30岁及以上女性。

主要观察指标

无乳腺癌病史女性中浸润性小叶癌和导管癌发病率的比例变化。

结果

本分析共纳入190458名通过登记处确诊为浸润性乳腺癌的女性;在198140名可能符合条件的女性(即那些被确定为无原位乳腺癌的女性)中,有7682名因癌症分期不明而被排除在本分析之外。经年龄和SEER历史分期调整后的浸润性乳腺癌发病率从1987年至1999年增加了1.04倍(95%置信区间[CI],1.004 - 1.07)(年龄调整后从206.7/10万增至214.1/10万)。然而,分类为小叶癌的发病率增加了1.52倍(95%CI,1.42 - 1.63),分类为导管 - 小叶混合型的发病率增加了1.96倍(95%CI,1.80 - 2.14);这两种类型的发病率合计增加了1.65倍(95%CI,1.55 - 1.78)(年龄调整后从19.8/10万增至33.4/10万)。相比之下,导管癌发病率基本保持不变(年龄调整后从153.8/10万增至155.3/10万;比例变化为1.03[95%CI,0.99 - 1.06])。含有小叶成分的乳腺癌比例从1987年的9.5%增至1999年的15.6%。

结论

1987年至1999年期间,导管癌发病率基本保持不变,而小叶癌发病率稳步上升。鉴于通过体格检查和乳房X线摄影,小叶癌比导管癌更难检测,这种上升带来了临床挑战。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验